Neuromod

Neuromod is a global medical technology company focused on innovative treatments for tinnitus, a condition affecting 10–15% of the population. Founded in 2010 by Dr. Ross O’Neill, the company is headquartered in Ireland and has offices in the US and Germany. Neuromod holds 136 patents and is dedicated to developing patient-centric neuromodulation technologies for neurological conditions. The company's flagship product, Lenire, is the first FDA-approved bimodal neuromodulation device for tinnitus treatment. It combines mild electrical pulses delivered to the tongue with auditory stimulation through headphones. This device is tailored to each patient's hearing profile and is used at home over a prescribed period. Lenire has been validated through three large-scale clinical trials with over 600 patients, demonstrating its safety and efficacy. Neuromod aims to redefine tinnitus care standards through scientific innovation and partnerships with healthcare providers, including collaborations with the U.S. Department of Veterans Affairs.

• Employees 52
• Founded 2010
• Annual Revenue $5500000
• Total Funding $83361770